Device Trial Radar · NCT06470022
Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,370
Actual
Start
Aug 9, 2024
Primary completion
Jul 14, 2027
Study completion Nov 20, 2036
Sponsor
- Lead sponsor
- Christian Juhl TerkelsenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark
- First posted
- Jun 24, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.
Conditions
- Aortic Stenosis
Interventions
Medtronic Evolut FXDevice
TAVI performed with Medtronic Evolut FX
Edwards Sapien 3 Ultra ResiliaDevice
TAVI performed with Edwards Sapien 3 Ultra Resilia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality, stroke, moderate/major aortic regurgitation, moderate/severe THV deteriorationTime frame: 1-year, 3-year, 5-year, 10-year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of cardiology, Aarhus University Hospital
Aarhus, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.